Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance

Revista Brasileira de Hematologia e Hemoterapia

Belinda Pinto Simões²  José Wilson Ramos Braga Junior¹  Maria Aparecida Do Carmo Rego¹  Cármino Antônio De Souza¹ 

[1] ,Universidade de São Paulo Faculdade de Medicina de Ribeirão Preto Ribeirão Preto SP ,Brazil

关键词: Leukemia;    myelogenous;    chronic;    BCR-ABL positive;    Drug resistance;    Drug monitoring;    neoplasm;    Receptor Protein-Tyrosine Kinases;    Pyrimidines;    Antineoplastic agents;    Monitoring;    Prognosis;   

DOI  :  10.5581/1516-8484.20110017

来源: SciELO

【 摘 要 】

Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better results

【 授权许可】

CC BY-NC-ND   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License